Alcobra Company Profile (NASDAQ:ADHD)

About Alcobra (NASDAQ:ADHD)

Alcobra logoAlcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADHD
  • CUSIP: N/A
  • Web: www.alcobra-pharma.com
Capitalization:
  • Market Cap: $31.42 million
  • Outstanding Shares: 27,562,000
Average Prices:
  • 50 Day Moving Avg: $1.16
  • 200 Day Moving Avg: $1.36
  • 52 Week Range: $0.83 - $5.36
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.38
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.61 per share
  • Price / Book: 0.71
Profitability:
  • EBIDTA: ($23,500,000.00)
  • Return on Equity: -45.21%
  • Return on Assets: -42.55%
Debt:
  • Current Ratio: 21.08%
  • Quick Ratio: 21.08%
Misc:
  • Average Volume: 360,159 shs.
  • Beta: 1.5
  • Short Ratio: 5.73
 

Frequently Asked Questions for Alcobra (NASDAQ:ADHD)

What is Alcobra's stock symbol?

Alcobra trades on the NASDAQ under the ticker symbol "ADHD."

How were Alcobra's earnings last quarter?

Alcobra Ltd. (NASDAQ:ADHD) issued its quarterly earnings data on Tuesday, May, 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. View Alcobra's Earnings History.

When will Alcobra make its next earnings announcement?

Alcobra is scheduled to release their next quarterly earnings announcement on Wednesday, August, 16th 2017. View Earnings Estimates for Alcobra.

Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?

9 brokers have issued 12-month price objectives for Alcobra's stock. Their forecasts range from $1.00 to $4.00. On average, they expect Alcobra's share price to reach $2.02 in the next twelve months. View Analyst Ratings for Alcobra.

What are analysts saying about Alcobra stock?

Here are some recent quotes from research analysts about Alcobra stock:

  • 1. According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (6/15/2017)
  • 2. Cantor Fitzgerald analysts commented, "Development of new drugs carries a high failure rate, either because the drug in question fails to show efficacy or significant safety issues arise during the clinical trial process. In addition, regulatory authorities such as the Food & Drug Administration (FDA) may delay the approval process or reject Alcobra’s clinical findings." (4/13/2017)

Who are some of Alcobra's key competitors?

Who are Alcobra's key executives?

Alcobra's management team includes the folowing people:

  • Yaron Daniely, Chairman of the Board
  • David C. Baker, Interim Chief Executive Officer and Chief Commercial Officer
  • Tomer Berkovitz, Chief Financial Officer
  • Hagit Marchaim Ph.D., Senior Vice President - Regulatory Affairs
  • Hanna Ron, Senior Vice President of Chemistry, Manufacturing and Control
  • Oded Edri, Vice President - Finance
  • Johanna Schumann, Vice President - Preclinical Development
  • Jonathan Rubin M.D., Chief Medical Officer
  • Daniel E. Geffken CPA, Director
  • Aharon Schwartz, Director

Who owns Alcobra stock?

Alcobra's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include EXODUS CAPITAL L.P. (16.80%), BROSH CAPITAL PARTNERS L.P. (16.50%), BROSH CAPITAL L.P. (12.00%), Broadfin Capital LLC (4.41%), Royce & Associates LP (0.00%) and Morgan Stanley (0.00%). View Institutional Ownership Trends for Alcobra.

Who sold Alcobra stock? Who is selling Alcobra stock?

Alcobra's stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Broadfin Capital LLC and Kingdon Capital Management L.L.C.. View Insider Buying and Selling for Alcobra.

Who bought Alcobra stock? Who is buying Alcobra stock?

Alcobra's stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Worth Venture Partners LLC, Citadel Advisors LLC and Royce & Associates LP. View Insider Buying and Selling for Alcobra.

How do I buy Alcobra stock?

Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alcobra's stock price today?

One share of Alcobra stock can currently be purchased for approximately $1.14.


MarketBeat Community Rating for Alcobra (NASDAQ ADHD)
Community Ranking:  2.7 out of 5 ( )
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Alcobra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $2.02 (77.32% upside)

Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017Jefferies Group LLCReiterated RatingHold$1.25LowView Rating Details
5/31/2017Roth CapitalSet Price TargetBuy$4.00HighView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00LowView Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/AView Rating Details
1/17/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 -> $2.00N/AView Rating Details
11/2/2016WBB SecuritiesUpgradeSell -> Hold$4.00 -> $1.90N/AView Rating Details
10/28/2016Barclays PLCDowngradeEqual Weight -> Underweight$3.00 -> $2.00N/AView Rating Details
9/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyN/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for Alcobra (NASDAQ:ADHD)
Earnings by Quarter for Alcobra (NASDAQ:ADHD)
Earnings History by Quarter for Alcobra (NASDAQ ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017        
5/30/20173/31/2017($0.15)($0.13)ViewN/AView Earnings Details
2/15/201712/31/2016($0.26)($0.22)ViewListenView Earnings Details
11/15/2016Q316($0.27)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/12/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015Q1 2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.61)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.58)($0.57)ViewListenView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alcobra (NASDAQ:ADHD)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.15)($0.20)
Q2 20172($0.23)($0.13)($0.18)
Q3 20172($0.18)($0.14)($0.16)
Q4 20172($0.19)($0.15)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Alcobra (NASDAQ:ADHD)
Latest Headlines for Alcobra (NASDAQ:ADHD)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Anticipate Alcobra Ltd. (ADHD) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - June 28 at 8:18 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 27 at 9:26 AM
streetinsider.com logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives
www.streetinsider.com - June 24 at 1:55 AM
streetinsider.com logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - StreetInsider.com
www.streetinsider.com - June 23 at 8:54 PM
finance.yahoo.com logoAlcobra Updates on its Review of Strategic Alternatives
finance.yahoo.com - June 23 at 3:52 PM
News IconUPDATE 1-Shire wins U.S. approval for long-acting ADHD drug
www.businessinsider.com - June 22 at 12:53 PM
nasdaq.com logoShire wins US approval for long-acting ADHD drug - Nasdaq
www.nasdaq.com - June 21 at 3:49 PM
nasdaq.com logoShire's long-acting ADHD drug wins US approval - Nasdaq
www.nasdaq.com - June 20 at 8:52 PM
americanbankingnews.com logoZacks Investment Research Lowers Alcobra Ltd. (ADHD) to Hold
www.americanbankingnews.com - June 15 at 8:50 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Enters Cooperation Agreement with Brosh ... - StreetInsider.com
www.streetinsider.com - June 13 at 5:40 AM
finance.yahoo.com logoAlcobra Announces Cooperation Agreement with Brosh Group and Board Additions
finance.yahoo.com - June 12 at 3:54 PM
americanbankingnews.com logoAlcobra's (ADHD) Hold Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - June 12 at 8:28 AM
streetinsider.com logoAlcobra Ltd. (ADHD) Gains on Rumors of Bid from Regenera - StreetInsider.com
www.streetinsider.com - June 9 at 3:25 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - June 2 at 8:34 PM
americanbankingnews.com logo Brokerages Anticipate Alcobra Ltd (ADHD) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - June 2 at 6:42 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) PT Set at $4.00 by Roth Capital
www.americanbankingnews.com - June 1 at 11:02 PM
nasdaq.com logoSwiss biotech NLS Pharma's ADHD drug succeeds in mid-stage ... - Nasdaq
www.nasdaq.com - May 31 at 3:19 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 31 at 10:02 AM
americanbankingnews.com logoAlcobra Ltd (ADHD) Announces Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 31 at 7:34 AM
globenewswire.com logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - May 30 at 10:07 AM
finance.yahoo.com logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 30 at 10:07 AM
finance.yahoo.com logoAlcobra reports 1Q loss
finance.yahoo.com - May 30 at 10:07 AM
streetinsider.com logoAlcobra (ADHD) CEO to Step Down, Remain on Board
www.streetinsider.com - May 16 at 8:20 PM
finance.yahoo.com logoChuck Royce Continues to Buy These 10 Stocks
finance.yahoo.com - May 16 at 8:20 PM
streetinsider.com logoAlcobra (ADHD) CEO to Step Down, Remain on Board - StreetInsider.com
www.streetinsider.com - May 15 at 3:20 PM
globenewswire.com logoAlcobra Announces Leadership Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 8:09 AM
finance.yahoo.com logoAlcobra Announces Leadership Update
finance.yahoo.com - May 15 at 8:09 AM
americanbankingnews.com logo Analysts Anticipate Alcobra Ltd (ADHD) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 9 at 8:24 AM
streetinsider.com logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting
www.streetinsider.com - May 7 at 3:20 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 5 at 9:08 PM
finance.yahoo.com logoAlcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group
finance.yahoo.com - May 5 at 8:21 PM
streetinsider.com logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - StreetInsider.com
www.streetinsider.com - May 5 at 3:20 PM
americanbankingnews.com logoAlcobra (ADHD) Getting Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 3 at 8:32 AM
americanbankingnews.com logoAlcobra (ADHD) Given Daily Media Sentiment Score of 0.22
www.americanbankingnews.com - April 30 at 11:17 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Very Unlikely to Impact Alcobra (ADHD) Stock Price
www.americanbankingnews.com - April 27 at 2:06 PM
globenewswire.com logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders - GlobeNewswire (press release)
globenewswire.com - April 24 at 3:21 PM
americanbankingnews.com logoAlcobra (ADHD) Receiving Somewhat Negative Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 24 at 11:48 AM
finance.yahoo.com logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders
finance.yahoo.com - April 24 at 11:00 AM
americanbankingnews.com logoAlcobra (ADHD) Receives Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 20 at 10:39 AM
americanbankingnews.com logoZacks Investment Research Lowers Alcobra Ltd (ADHD) to Hold
www.americanbankingnews.com - April 18 at 9:57 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 18 at 1:22 PM
americanbankingnews.com logoAlcobra (ADHD) Earns Coverage Optimism Rating of 0.18
www.americanbankingnews.com - April 17 at 10:08 AM
americanbankingnews.com logoZacks Investment Research Upgrades Alcobra Ltd (ADHD) to Buy
www.americanbankingnews.com - April 17 at 7:36 AM
americanbankingnews.com logoAlcobra (ADHD) Receiving Positive Media Coverage, Report Finds
www.americanbankingnews.com - April 14 at 1:54 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Given "Hold" Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 13 at 9:20 PM
finance.yahoo.com logoExodus Capital is Summoning an Extraordinary General Meeting
finance.yahoo.com - April 12 at 12:11 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 11 at 10:58 PM
americanbankingnews.com logoAlcobra Ltd (ADHD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 10 at 8:51 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Rejects Brosh Capital's Request to Hold Extraordinary General Meeting
www.streetinsider.com - April 7 at 3:21 PM
finance.yahoo.com logoTenax Therapeutics and Alcobra Find Rough Waters Ahead
finance.yahoo.com - April 7 at 3:21 PM

Social

Chart

Alcobra (ADHD) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff